Highlights

  • Telix reported US$477 million in H1 2026 group revenue, a 22% year-on-year increase.
  • Group gross margin reached 55%, while adjusted EBITDA was US$52 million.
  • Research and development investment totalled US$124 million during the half-year.
  • The Phase 3 BiPASS study completed enrolment of 350 patients in September 2026.
  • Telix continued developing precision imaging and targeted therapeutic candidates across multiple cancers.

Telix Pharmaceuticals Limited (ASX:TLX) develops and commercialises targeted radiopharmaceuticals for cancer imaging and treatment. Its precision medicine portfolio includes prostate-specific membrane antigen (PSMA) imaging agents, alongside investigational products for kidney and brain cancers. During 2026, the company reported higher first-half revenue and advanced clinical research intended to extend the applications of its imaging technologies.

H1 2026 Revenue and Operating Results

For the six months ended 30 June 2026, Telix Pharmaceuticals Limited (ASX:TLX) reported group revenue of US$477 million, an increase of 22% year on year. Group gross margin was 55%, an improvement of two percentage points, while the precision medicine business recorded a gross margin of 65%, up one percentage point. These figures reflect the company’s reported sales mix and operating performance during the period.

Adjusted EBITDA reached US$52 million, representing a 146% year-on-year increase. The company disclosed that this measure included a US$40 million initial non-refundable payment from its Regeneron collaboration. Accordingly, the payment is relevant when interpreting the reported EBITDA change rather than treating the increase entirely as recurring product earnings.

Telix Pharmaceuticals Limited (ASX:TLX) reported US$124 million in research and development investment during H1 2026. Spending was directed primarily towards later-stage therapeutic and precision medicine programs. Management also stated full-year 2026 revenue guidance of US$950 million to US$970 million in its August results release; that range is company guidance, not a reported full-year outcome.

PSMA Imaging and the BiPASS Study

Telix markets Illuccix and Gozellix, gallium-68 PSMA imaging products used in prostate cancer care. PSMA-targeting agents are designed to bind to a protein expressed by many prostate cancers, allowing positron emission tomography (PET) imaging to reveal areas of radiotracer uptake. Imaging results require clinical interpretation and do not, by themselves, establish treatment effectiveness.

On 2 September 2026, Telix Pharmaceuticals Limited (ASX:TLX) announced completion of enrolment in its Phase 3 BiPASS study, involving 350 patients. The study evaluates gallium-68 PSMA-11 PET alongside MRI for detection of prostate cancer before biopsy. The company also reported engagement with the US Food and Drug Administration on a potential New Drug Application pathway. Enrolment completion does not constitute regulatory approval or demonstrate that the study met its endpoints.

Different Cancer Targets and Development Pathways

PSMA is one part of the company’s radiopharmaceutical strategy. Its imaging pipeline also includes TLX250-Px, known as Zircaix, which targets carbonic anhydrase IX (CAIX) in clear-cell renal cell carcinoma. Other investigational assets include imaging and therapeutic candidates for neurologic oncology. These programs differ in their target molecules, radioactive isotopes, intended uses and development stages.

Telix Pharmaceuticals Limited (ASX:TLX) has also identified pivotal-stage therapeutic research in prostate cancer, recurrent glioblastoma and kidney cancer. Product development depends on clinical evidence, manufacturing controls and regulatory decisions. The existence of a clinical program or an agency submission should not be confused with an authorised clinical indication.

Operational Factors and Risks

Radiopharmaceutical operations require reliable isotope production, qualified manufacturing facilities and coordinated distribution because radioactive materials have time-sensitive handling requirements. Telix Pharmaceuticals Limited (ASX:TLX) is therefore exposed to manufacturing scale-up, supply continuity and country-specific regulatory requirements. Clinical study outcomes, reimbursement arrangements and development expenditure can also affect operating performance.

Key Insights

Telix’s 2026 disclosures show a business combining commercial cancer imaging products with continued investment in therapeutic development. H1 revenue, gross margin and research spending provide measurable context for its operations, while BiPASS enrolment marks a defined clinical milestone. The distinction between marketed diagnostic products, investigational applications and company-issued guidance remains important when interpreting subsequent announcements.